E7070

Phase 2Completed
1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Breast Neoplasms

Conditions

Breast Neoplasms, Metastases

Trial Timeline

Feb 1, 2004 → May 1, 2005

About E7070

E7070 is a phase 2 stage product being developed by Eisai for Breast Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT00080197. Target conditions include Breast Neoplasms, Metastases.

What happened to similar drugs?

20 of 20 similar drugs in Breast Neoplasms were approved

Approved (20) Terminated (4) Active (0)

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (6)

NCT IDPhaseStatus
NCT00165867Phase 2Completed
NCT00165594Phase 1/2Terminated
NCT00165880Phase 2Terminated
NCT00080197Phase 2Completed
NCT00165854Phase 2Completed
NCT00059735Phase 2Completed

Competing Products

20 competing products in Breast Neoplasms

See all competitors
ProductCompanyStageHype Score
Intratumoral Mitazalimab + Intratumoral NivolumabAlligator Bioscience ABPhase 1
26
FulvestrantDr. Reddy's LaboratoriesPre-clinical
19
LymphoseekNavidea BiopharmaceuticalsPhase 3
30
LymphoseekNavidea BiopharmaceuticalsPhase 3
30
ALT-P7 (HM2-MMAE)AlteogenPhase 1
29
Biomarkers blood, urine and microbiota samplesEli LillyPre-clinical
30
gemcitabine + paclitaxel + bevacizumabEli LillyPhase 2
35
Gemcitabine + Adriamycine + PaclitaxelEli LillyPhase 2
35
Abemaciclib + FulvestrantEli LillyPhase 2
27
VS-6766 + Abemaciclib + FulvestrantEli LillyPhase 1/2
39
gemcitabine + vinorelbineEli LillyPhase 2
35
Abemaciclib + Fulvestrant + PlaceboEli LillyPhase 3
44
Azenosertib + Carboplatin + PembrolizumabZentalis PharmaceuticalsPhase 1/2
26
AbemaciclibEli LillyPre-clinical
26
pemetrexed + cyclophosphamide + doxorubicin + docetaxelEli LillyPhase 2
35
arzoxifeneEli LillyApproved
43
BBI-355 + Erlotinib + Futibatinib + BBI-825Boundless BioPhase 1
23
BBI-940 + FulvestrantBoundless BioPhase 1
26
LY4064809 + Placebo + Ribociclib + Palbociclib + Abemaciclib + Anastrozole + Letrozole + Exemestane + FulvestrantEli LillyPhase 3
47
pemetrexed + gemcitabineEli LillyPhase 2
35